Log in

ASX:VLS - Vita Life Sciences Stock Price, Forecast & News

Today's Range N/A
50-Day Range
A$0.67
MA: A$0.71
A$0.75
52-Week Range N/A
Volume2,815 shs
Average VolumeN/A
Market Capitalization$38.44 million
P/E Ratio15.80
Dividend Yield5.28%
BetaN/A
Vita Life Sciences Limited, a pharmaceutical and healthcare company, engages in formulation, packaging, sale, and distribution of vitamins and supplements. It offers a range of supplements, vitamins, minerals, herbs, and superfoods. The company markets its products through pharmacies and health food stores under the VitaHealth, Herbs of Gold, VitaScience, and VitaLife brand names. It operates in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, Hong Kong, and China. Vita Life Sciences Limited was founded in 1947 and is headquartered in Melbourne, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9828 0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$41.44 million
Book ValueA$0.38 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$38.44 million
Next Earnings DateN/A
OptionableNot Optionable

Receive VLS News and Ratings via Email

Sign-up to receive the latest news and ratings for VLS and its competitors with MarketBeat's FREE daily newsletter.


Vita Life Sciences (ASX:VLS) Frequently Asked Questions

What is Vita Life Sciences' stock symbol?

Vita Life Sciences trades on the ASX under the ticker symbol "VLS."

How often does Vita Life Sciences pay dividends? What is the dividend yield for Vita Life Sciences?

Vita Life Sciences declared a Interim dividend on Friday, September 13th. Stockholders of record on Tuesday, October 8th will be given a dividend of 0.015 per share on Tuesday, October 8th. This represents a dividend yield of 2.21%. The ex-dividend date is Tuesday, September 24th. View Vita Life Sciences' Dividend History.

Has Vita Life Sciences been receiving favorable news coverage?

News headlines about VLS stock have trended positive on Friday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vita Life Sciences earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Vita Life Sciences.

Who are some of Vita Life Sciences' key competitors?

Who are Vita Life Sciences' key executives?

Vita Life Sciences' management team includes the folowing people:
  • Mr. Andrew O'Keefe, MD & Director
  • Mr. Chin Leng Khoo, CFO & Company Sec.
  • Ms. Melissa Pereira, Head of Marketing
  • Mr. Edward Choop, Chief Exec. Officer of Asia Pacific
  • K. S. Beh, Head of Operations for Asia Pacific

How big of a company is Vita Life Sciences?

Vita Life Sciences has a market capitalization of $0.00 and generates $41.44 million in revenue each year. View Additional Information About Vita Life Sciences.

What is Vita Life Sciences' official website?

The official website for Vita Life Sciences is http://www.vitalifesciences.com/.

How can I contact Vita Life Sciences?

The company can be reached via phone at 61 3 9828 0500.


MarketBeat Community Rating for Vita Life Sciences (ASX VLS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  17 (Vote Underperform)
Total Votes:  34
MarketBeat's community ratings are surveys of what our community members think about Vita Life Sciences and other stocks. Vote "Outperform" if you believe VLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel